Rhythm Pharmaceuticals, Inc.
Clinical trials sponsored by Rhythm Pharmaceuticals, Inc., explained in plain language.
-
New hope for rare obesity: setmelanotide safety trial expands
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called setmelanotide in people aged 2 and older with rare genetic obesity. Participants must have already been in a setmelanotide study and shown benefit. The goal is to monitor side effects over time.
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 08:50 UTC
-
New hope for rare obesity: 2-Year drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effects of a drug called bivamelagon in 25 people with hypothalamic obesity, a rare condition causing severe weight gain. Participants who completed a prior study will take the drug for up to 2 years. Researchers will monitor side effects…
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 08:48 UTC
-
Promising drug targets severe hunger and obesity in rare genetic disorder
Disease control OngoingThis study tests a daily injection called setmelanotide in people aged 6 to 65 with Prader-Willi syndrome, a genetic condition causing severe obesity and constant hunger. The goal is to see if the drug is safe and helps reduce body weight and hunger over 52 weeks. Up to 18 partic…
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug targets genetic obesity in phase 3 trial
Disease control OngoingThis study tests a drug called setmelanotide for people with obesity caused by specific gene variants (POMC, PCSK1, LEPR, SRC1, or SH2B1). About 296 participants aged 6 to 65 will receive either the drug or a placebo to see if it helps reduce body weight. The goal is to control o…
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC